Insulet(PODD)
Focus: Insulet is a public medical device company specializing in insulin delivery systems, primarily the Omnipod platform for diabetes management. The company operates at ~300-500 employees with $1.7B in FY2025 revenue, positioning it as a dominant player in the automated insulin delivery market.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
201-500
Open Jobs
312+102 this month
Hot — 296 jobs added in 30d
Net +102 (296 new, 194 removed). Aggressive expansion phase.
Should You Work at Insulet?
AI assessmentInsulet is a high-growth, profitable medical device company ideal for engineers and commercial talent seeking stability with strong visa sponsorship, but offers limited exposure to traditional drug development or early-stage discovery science.
Why Work Here
- Strong revenue growth trajectory ($1.3B→$1.7B YoY) with profitability inflection ($5M→$206M net income), signaling financial stability and reinvestment capacity
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$1.7B
Key Products
Omnipod 5 Automated Glucose Control System
Growing
Growth
Flagship closed-loop insulin delivery platform driving revenue growth and clinical adoption across both diabetes types.
Omnipod Horizon™ Automated Glucose Control System
Help build intelligence for Insulet
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.